Ben Markman
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 21
- Colorectal Cancer Treatments and Studies 15
- Lung Cancer Research Studies 15
- HER2/EGFR in Cancer Research 10
- Cancer Treatment and Pharmacology 9
- Cancer Research top 5%
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 7
- Molecular Biology top 5%
-
- Lung Cancer Treatments and Mutations 12
-
- Monoclonal and Polyclonal Antibodies Research 8
- Co-authors
- Josep TaberneroRodrigo DienstmannJosé BaselgaFrancesco AtzoriMaurizio ScaltritiVioleta SerraVanesa ValeroCarlos Garcı́a-Echeverrı́a
- Cited by
- OncologyCancer ResearchGenetics
- Journals
- Journal of Clinical Oncology (26 papers)Annals of Oncology (8 papers)Cancer Research (4 papers)
- Partner nations
- AustraliaUnited StatesSpain
In The Last Decade
Ben Markman
72 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 1.2k
- Cancer Research 329
- Genetics 229
- Molecular Biology 1.3k
- Pathology and Forensic Medicine 334
Countries citing papers authored by Ben Markman
This map shows the geographic impact of Ben Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Markman more than expected).
Fields of papers citing papers by Ben Markman
This network shows the impact of papers produced by Ben Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Markman. The network helps show where Ben Markman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ben Markman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A gut microbial signature for combination immune checkpoint blockade across cancer typesbreakdown → | 2024 | 67 |
| 2 | 2023 | 10 | |
| 3 | 2023 | 35 | |
| 4 | Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors | 2022 | 40 |
| 5 | 2020 | 116 | |
| 6 | 2020 | 4 | |
| 7 | A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors | 2019 | 3 |
| 8 | 2017 | 2 | |
| 9 | 2017 | 57 | |
| 10 | 2017 | 35 | |
| 11 | 2016 | 1 | |
| 12 | 2016 | 13 | |
| 13 | 2016 | 3 | |
| 14 | 2014 | 87 | |
| 15 | 2012 | 29 | |
| 16 | 2010 | 4 | |
| 17 | 2010 | 19 | |
| 18 | 2009 | 127 | |
| 19 | 2009 | 4 | |
| 20 | NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutationsbreakdown → | 2008 | 626 |
About Ben Markman
Ben Markman is a scholar working on Oncology, Biological Psychiatry and Genetics, having authored 75 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (21 papers), Colorectal Cancer Treatments and Studies (15 papers), Lung Cancer Research Studies (15 papers), Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). The work is most often cited by research in Oncology (1.2k citations), Cancer Research (329 citations) and Genetics (229 citations). Ben Markman has collaborated with scholars based in Australia, United States and Spain. Frequent co-authors include Josep Tabernero, Rodrigo Dienstmann, José Baselga, Francesco Atzori, Maurizio Scaltriti, Violeta Serra, Vanesa Valero, Carlos Garcı́a-Echeverrı́a, Elisabeth Llonch and Josep Lluís Parra. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.